JanOne Inc., a company focused on reducing opioid addiction by finding treatments for conditions accompanied by pain and bringing to market drugs and therapies with nonaddictive pain-relieving properties, recently announced a licensing agreement for TV1001SR, a treatment for Peripheral Artery Disease (PAD), a disease in which plaque builds up in the arteries that carry blood to your head, organs, and limbs.
The TV1001SR treatment was invented by Christopher Kevil, PhD, Professor of Pathology, Molecular and Cellular Physiology, and Cell Biology and Anatomy at LSU Health Shreveport. In initial research studies, the drug effectively restored ischemic (or restricted) tissue blood flow and was effective in a wide range of disease causes and effects involving alterations of angiogenesis (the development of new blood vessels) including diabetes, wound healing and tissue necrosis. Dr. Kevil will continue working with JanOne to further develop this critical medication for people who are suffering from PAD-associated pain.
